Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07083011 · ClinicalTrials.gov registry record · Phase 2
A Study of 68Ga-Fibroblast Activation Protein Inhibitor (FAPI) Positron Emission Tomography in Heart Failure
A Phase 2 study of Heart Failure With Preserved Ejection Fraction, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT07083011: Recruiting Phase 2 study of Heart Failure With Preserved Ejection Fraction, sponsored by Mayo Clinic.
NCT07083011 is a Phase 2 study of Heart Failure With Preserved Ejection Fraction that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 35 participants, below the 2,287-participant average among 42 other Heart Failure With Preserved Ejection Fraction trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07083011, a Phase 2 study of Heart Failure With Preserved Ejection Fraction, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess the performance of 68Ga- FAPI PET in heart failure with preserved ejection fraction (HFpEF)
Primary Outcome
Myocardial 68Ga-FAPI volume will be determined by a PET (positron emission tomography) scan and measured in cm3
Conditions Studied
Interventions
- DRUG 68Ga-FAPI (gallium-68-labeled fibroblast activation protein inhibitor)
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2025-11 |
| Est. Completion | 2027-07 |
| Phase | Phase 2 |
What NCT07083011 shows while recruiting
NCT07083011 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 2,287-participant average among 42 other Heart Failure With Preserved Ejection Fraction trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Heart Failure With Preserved Ejection Fraction appearing as the primary indexed condition, and to 1 intervention - of which 68Ga-FAPI (gallium-68-labeled fibroblast activation protein inhibitor) is the first listed.
NCT07083011 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT07083011 about?
NCT07083011 is a clinical study titled "A Study of 68Ga-Fibroblast Activation Protein Inhibitor (FAPI) Positron Emission Tomography in Heart Failure". The purpose of this study is to assess the performance of 68Ga- FAPI PET in heart failure with preserved ejection fraction (HFpEF)
What is the current status of trial NCT07083011?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2025-11. Estimated completion is 2027-07.
What conditions does trial NCT07083011 study?
This clinical trial studies the following conditions: Heart Failure With Preserved Ejection Fraction.
What interventions are being tested in trial NCT07083011?
The interventions under investigation include: 68Ga-FAPI (gallium-68-labeled fibroblast activation protein inhibitor) (DRUG).
Who is sponsoring clinical trial NCT07083011?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07083011 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure With Preserved Ejection Fraction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07083011's enrollment target sits among peer trials
35 30th of 42 higher than 13 of 42 other Heart Failure With Preserved Ejection Fraction trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure With Preserved Ejection Fraction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Matching Perfusion and Metabolic Activity in HFpEF
RECRUITING · Phase 2
-
SGLT2i and KNO3 in HFpEF - The SAK HFpEF Trial
RECRUITING · Phase 2
-
Study of JK07 in Patients With Chronic Heart Failure
RECRUITING · Phase 2
-
A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)
RECRUITING · Phase 2
-
Metformin for Older Patients With Heart Failure With Preserved Ejection Fraction
ACTIVE NOT RECRUITING · Phase 2
-
Cilostazol for HFpEF
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia